News Search Results
Sep 03, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Sep 03, 2025, 09:02 ET Julius Clinical Expands CNS and Cardiometabolic Capabilities with Post-Merger Growth and New Operations in Spain and Germany
2025 /PRNewswire/ -- Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic indications, today announced continued growth in bookings in these key therapeutic areas during the second quarter of 2025. This
More news about: Julius Clinical
Sep 02, 2025, 17:02 ET 3-minute EEG Test Reliably Detects Memory Impairment, Enabling Earlier Alzheimer's Diagnosis
NeuroscienceWith a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq®, an AI-based, multi-domain digital biomarker
More news about: Cumulus Neuroscience
Sep 02, 2025, 08:00 ET CRC Appoints Jason Casarella, MBA as Chief Commercial Officer
chapter of growth as the partner of choice in CNS clinical research. About Cognitive Research CorporationCognitive Research Corporation (CRC) is a leading full-service clinical research organization, specializing exclusively in CNS disorders, including neurology, psychiatry, and
More news about: Cognitive Research Corporation
Aug 29, 2025, 10:44 ET Expert Panel to Discuss Innovations in Alzheimer's Disease Clinical Trials
academia on the transformative power of at-home and in-clinic innovations in central nervous system (CNS) clinical trials. Attendees will learn how digital biomarkers have the potential to transform CNS clinical trials much the same way that next-generation sequencing has transformed oncology, enabling
More news about: Xtalks
Aug 29, 2025, 08:00 ET Nota AI Showcases Generative AI-Based Next-Gen Traffic Innovation at ITSWC 2025, Demonstrating Leadership on the Global Stage
Successful U.S. PoC with Sony underscores accelerated global market expansionJoint showcases with Korea Pavilion, hosted by MOLIT•LG CNS highlight Korea's leadership and the global competitiveness of ITS technologySEOUL,
More news about: Nota AI
Aug 29, 2025, 01:23 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
maximum daily dose of 12 mL; essentially 'sodium-free'. Contains glucose - may be harmful to teeth. Interactions: Pharmacodynamic interactions with other CNS depressants increase the risk of aggravated central nervous system depression. An increase in dose may be necessary when coadministered with rifampicin
More news about: UCB
Aug 29, 2025, 01:15 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
maximum daily dose of 12 mL; essentially 'sodium-free'. Contains glucose - may be harmful to teeth. Interactions: Pharmacodynamic interactions with other CNS depressants increase the risk of aggravated central nervous system depression. An increase in dose may be necessary when coadministered with rifampicin
More news about: UCB
Aug 28, 2025, 18:27 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 18:22 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 18:22 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 18:19 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 18:17 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 17:31 ET GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight
nuclear GSK-3β. AMO Pharma is developing AMO-02 (tideglusib) for congenital myotonic dystrophy, with potential applications in other CNS, neuromuscular, and orphan diseases. This clinical-stage investigational drug targets the severe form of congenital myotonic dystrophy (DM1 or Steinert
More news about: DelveInsight Business Research, LLP
Aug 28, 2025, 09:00 ET D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
protein. In preclinical investigations, D3S-001 demonstrated high covalent potency, complete engagement of KRAS G12C at clinically relevant doses and CNS penetration properties. D3S-001 is currently under evaluation as monotherapy and in combination regimens in a Phase II global clinical trial in patients
More news about: D3 Bio, Inc.
Aug 28, 2025, 08:30 ET Innovations in Alzheimer's Disease Clinical Trials: Digital Endpoints - Upcoming Expert Panel Discussion Hosted by Xtalks
academia on the transformative power of at-home and in-clinic innovations in central nervous system (CNS) clinical trials. Attendees will learn how digital biomarkers have the potential to transform CNS clinical trials much the same way that next-generation sequencing has transformed oncology, enabling
More news about: Xtalks
Aug 28, 2025, 07:00 ET Major European Financial Institution Selects Corero Network Security in Multi-Year Deal to Safeguard Critical Infrastructure
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced it has secured a multi-year
More news about: Corero Network Security
Aug 27, 2025, 17:31 ET Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight
while aggressive lymphomas demand intensive chemotherapy protocols often supplemented with prophylactic measures to prevent central nervous system (CNS) involvement. The emphasis on multidisciplinary care and supportive therapies to mitigate side effects is further enhancing patient outcomes and influencing
More news about: DelveInsight Business Research, LLP
Aug 27, 2025, 10:40 ET Harbour BioMed Reports 2025 Interim Results
for central nervous system (CNS) disorders, including bispecific antibodies and other "Antibody-Plus (Ab+)" therapies. The pipeline in this area is currently under development, with the goal of creating more complex molecules to address the treatment challenges of CNS disorders, including neurodegenerative
More news about: Harbour BioMed
Aug 27, 2025, 10:20 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Aug 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Aug 27, 2025, 07:00 ET Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
Worcester, Mass. Leal's lead programs address the critical intersection between CNS and metabolic disorders. The Leal team has particular expertise in CNS therapeutic development, as well as leveraging human genetics, functional genomics and biomarker analyses to support
More news about: Leal Therapeutics
Aug 26, 2025, 10:01 ET Neurology Devices Market Size to Reach US$ 43.28 Billion by 2033 - Exclusive Report by DataM Intelligence
sophisticated healthcare infrastructure in the U.S. and Canada. The region benefits from a large patient base with CNS disorders, including Alzheimer's, which affects over 5 million Americans, with projections estimating 16 million by 2050, according to the Alzheimer's
More news about: DataM Intelligence 4 Market Research LLP
Aug 25, 2025, 13:04 ET Human Longevity Taps Alamar Biosciences to Power Proteomic Innovation in Longevity Research
provides precise detection and monitoring of chronic inflammation, a central driver of aging and multiple age-related diseases.NULISAseq CNS Disease Panel 120 – enables early detection and monitoring of key biomarkers involved in neurodegenerative and neurological disorders, aiming to
More news about: Human Longevity, Inc.
Aug 22, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP